Compiling results of two large studies, researchers have identified biomarkers of response to aspirin among those taking the oral drug either as a way to treat or prevent colorectal cancer. The analysis shows that the effect of aspirin on colorectal cancer depends on whether or not the cancer harbors a BRAF mutation: those cancers that were BRAF mutated were less sensitive to aspirin. Read more here.
Study mentioned: Nishihara R, et al. Aspirin Use and Risk of Colorectal Cancer According to BRAF Mutation Status. JAMA. 2013 Jun 26;309(24):2563-71. PMID: 23800934
No comments:
Post a Comment